Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:PTCT NASDAQ:SRRK NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$23.53-1.3%$22.18$13.40▼$25.23$3.99B0.71.63 million shs1.75 million shsPTCTPTC Therapeutics$52.13+0.0%$49.21$29.01▼$58.38$4.13B0.541.12 million shs1.02 million shsSRRKScholar Rock$36.36-1.9%$35.27$6.76▼$46.98$3.52B0.481.15 million shs1.42 million shsSYRESpyre Therapeutics$16.26-4.2%$16.19$10.91▼$40.26$1.02B2.82540,586 shs551,674 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.26%+1.20%+10.78%+57.81%+23.71%PTCTPTC Therapeutics+0.04%+16.52%+6.06%+4.36%+54.00%SRRKScholar Rock-1.86%-6.65%+2.28%+10.48%+300.44%SYRESpyre Therapeutics-4.18%-8.60%+4.90%+7.61%-40.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.0001 of 5 stars3.43.00.00.02.54.22.5PTCTPTC Therapeutics4.4836 of 5 stars4.32.00.04.43.00.81.3SRRKScholar Rock3.8123 of 5 stars2.61.00.04.43.33.30.6SYRESpyre Therapeutics2.3063 of 5 stars3.60.00.00.02.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.71Moderate Buy$28.1319.53% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$69.3833.10% UpsideSRRKScholar Rock 3.22Buy$44.1421.40% UpsideSYRESpyre Therapeutics 3.29Buy$53.40228.41% UpsideCurrent Analyst Ratings BreakdownLatest SYRE, SRRK, ACAD, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetStrong-Buy$53.007/29/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $86.007/29/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$42.00 ➝ $46.007/29/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$68.00 ➝ $84.007/29/2025PTCTPTC TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$71.00 ➝ $80.007/29/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$112.00 ➝ $120.007/29/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$74.00 ➝ $78.007/28/2025PTCTPTC TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $50.007/24/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $34.007/17/2025SRRKScholar RockCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.11$0.70 per share33.81$4.40 per share5.35PTCTPTC Therapeutics$806.78M5.12N/AN/A($14.24) per share-3.66SRRKScholar Rock$33.19M104.02N/AN/A$3.94 per share9.23SYRESpyre Therapeutics$890K1,101.30N/AN/A$7.04 per share2.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3717.1830.966.6322.97%17.46%10.75%8/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.518.01N/AN/A33.56%-78.56%32.11%8/7/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)SYRESpyre Therapeutics-$208.02M-$3.77N/AN/AN/AN/A-77.46%-41.06%8/6/2025 (Estimated)Latest SYRE, SRRK, ACAD, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07N/AN/AN/A$173.01 millionN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$263.07 millionN/A8/6/2025Q2 2025SRRKScholar Rock-$0.68N/AN/AN/AN/AN/A8/6/2025Q2 2025SYRESpyre Therapeutics-$0.68N/AN/AN/AN/AN/A5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/8/2025Q1 2025SYRESpyre Therapeutics-$0.76-$0.74+$0.02-$0.74N/AN/A5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80PTCTPTC TherapeuticsN/A3.893.85SRRKScholar Rock0.1610.2510.25SYRESpyre TherapeuticsN/A8.068.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%PTCTPTC TherapeuticsN/ASRRKScholar Rock91.08%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%PTCTPTC Therapeutics5.50%SRRKScholar Rock13.30%SYRESpyre Therapeutics15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million123.01 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionableSYRESpyre Therapeutics7360.28 million50.98 millionOptionableSYRE, SRRK, ACAD, and PTCT HeadlinesRecent News About These CompaniesJefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)2 hours ago | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsAugust 1 at 4:41 PM | globenewswire.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on WednesdayJuly 31 at 6:49 AM | marketbeat.comVictory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)July 28, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by AnalystsJuly 17, 2025 | marketbeat.comHere's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn SituationJuly 16, 2025 | finance.yahoo.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?July 15, 2025 | marketbeat.comSYRE - Spyre Therapeutics Inc Trailing Returns - MorningstarJuly 4, 2025 | morningstar.comMSpyre Therapeutics Announces Grants of Inducement AwardsJuly 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)June 20, 2025 | theglobeandmail.comSpyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardJune 18, 2025 | seekingalpha.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...June 17, 2025 | finanznachrichten.deSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 ReadoutsJune 17, 2025 | prnewswire.comSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025June 16, 2025 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsJune 6, 2025 | prnewswire.comWall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should KnowMay 30, 2025 | zacks.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 28, 2025 | prnewswire.comHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%May 13, 2025 | zacks.comAnalysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)May 10, 2025 | theglobeandmail.comSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYRE, SRRK, ACAD, and PTCT Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$23.53 -0.30 (-1.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.17 -0.36 (-1.53%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.PTC Therapeutics NASDAQ:PTCT$52.13 +0.02 (+0.04%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$51.61 -0.52 (-1.01%) As of 08/1/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Scholar Rock NASDAQ:SRRK$36.36 -0.69 (-1.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$36.36 +0.01 (+0.01%) As of 08/1/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$16.26 -0.71 (-4.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$16.26 0.00 (0.00%) As of 08/1/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
